{"id":"NCT00827242","sponsor":"Eli Lilly and Company","briefTitle":"Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multinational Study to Evaluate the Efficacy and Safety of Daily Tadalafil for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-01","primaryCompletion":"2009-11","completion":"2009-11","firstPosted":"2009-01-22","resultsPosted":"2010-11-17","lastUpdate":"2010-11-17"},"enrollment":325,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Benign Prostatic Hyperplasia"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"tadalafil","otherNames":["Cialis","LY450190"]}],"arms":[{"label":"Tadalafil","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether an experimental drug known as tadalafil given once daily can reduce the symptoms associated with Benign Prostatic Hyperplasia (straining, urinary frequency, feeling like your bladder is still full, etc.)","primaryOutcome":{"measure":"Change From Baseline to 12 Weeks, International Prostate Symptom Score (IPSS)","timeFrame":"Baseline, 12 weeks","effectByArm":[{"arm":"Tadalafil","deltaMin":-5.6,"sd":0.47},{"arm":"Placebo","deltaMin":-3.6,"sd":0.47}],"pValues":[{"comp":"OG000 vs OG001","p":"0.004"}]},"eligibility":{"minAge":"45 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":8},"locations":{"siteCount":27,"countries":["United States","Argentina","Germany","Italy","Mexico"]},"refs":{"pmids":["26299520","21871706"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":161},"commonTop":["Back pain","Headache","Nasopharyngitis","Hypertension","Influenza"]}}